Status:
COMPLETED
Pilot Studie of Lipiodol Demarcation of the Tumour in Bladder Cancer
Lead Sponsor:
University of Aarhus
Collaborating Sponsors:
Aarhus University Hospital
Conditions:
Bladder Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Rationale: Bladder tumours are often not visible on X-ray based image-modalities during planning and treatment of Radiotherapy. Purpose: To determine if a single contrast (Lipiodol) demarcation of th...
Detailed Description
To exploit the potential of modern Radiotherapy (RT), it is important to localize and follow the target precisely during treatment. Since the bladder tumour can usually not be identified on convention...
Eligibility Criteria
Inclusion
- Histologically confirmed primary muscle invasive transitional cell carcinoma of the Bladder. T1-4a, N0-1, M0.
- Non-operable or refuse operation.
- Eligible for curative Radiotherapy.
- Oral and written informed consent.
- Fertile women must have a negative pregnancy test before inclusion or use contraceptive pills or intrauterine device.
- Ongoing beta blocker treatment is paused before Lipiodol injection.
Exclusion
- Known metabolic disorder (hyperthyroidism, goiter)
- Allergy towards iodine.
- Pregnancy / breast-feeding
- Performance status ECOG \> 2
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT00609843
Start Date
February 1 2008
End Date
April 1 2009
Last Update
December 7 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Oncology department of Aarhus Sygehus, Aarhus University Hospital
Aarhus, Central Jutland, Denmark, 8000